The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
Aaron R Lim,
W Kimryn Rathmell,
Jeffrey C Rathmell
Affiliations
Aaron R Lim
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, United States
W Kimryn Rathmell
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, United States; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States; Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, United States
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States; Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, United States; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, United States
Breakthroughs in anti-tumor immunity have led to unprecedented advances in immunotherapy, yet it is now clear that the tumor microenvironment (TME) restrains immunity. T cells must substantially increase nutrient uptake to mount a proper immune response and failure to obtain sufficient nutrients or engage the appropriate metabolic pathways can alter or prevent effector T cell differentiation and function. The TME, however, can be metabolically hostile due to insufficient vascular exchange and cancer cell metabolism that leads to hypoxia, depletion of nutrients, and accumulation of waste products. Further, inhibitory receptors present in the TME can inhibit T cell metabolism and alter T cell signaling both directly and through release of extracellular vesicles such as exosomes. This review will discuss the metabolic changes that drive T cells into different stages of their development and how the TME imposes barriers to the metabolism and activity of tumor infiltrating lymphocytes.